TABLE 3.

Clinical features of patients and characteristics of A. baumannii isolates with blaSIM-1 cassette-carrying class 1 integrons

Patient no.IsolateaAge (yrs)/sexUnderlying diseaseHospital wardDays since admissionbPrevious antimicrobial therapy (days)cSpecimen/ diagnosiscMIC (μg/ml)cPFGE pattern
SAMPIPCTXCAZFEPATMIPMMEMGENTOBAMKCIP
103/9/T1049/FCerebral palsyIntensive care unit30MEM (12), ATM (9), FEP (5)Sputum/ pneumonia1664>256>2566412881616161280.5A1
204/5/U226666/FHypothyroidism, osteoporosis, hypertensionOutpatientNAROX (10)Urine/UTI1664>256>2566412881616161280.5A1
304/8/U157564/MHerniated lumbar discInternal medicine9FMX (7)Urine/UTI1632>256>25664128161616161280.5A2
404/11/U181745/MIntracranial hemorrhageInternal medicine11ISP (8), CTX (7), CFM (4)Urine/UTI1632>256>2566412881616161280.5A2
504/12/U57513/MChronic myelogenous leukemiaPediatrics4NoneUrine/UTI16128>256>256128128161616161280.5B1
604/12/U8375/MAcute lymphocytic leukemiaPediatrics3AMC (4)Urine/UTI16256>256>2566412881616161280.5B1
704/12/U13983/MAcute myelogenous leukemiaPediatrics3SXT (3), AMC (2), ISP (2)Urine/UTI16128>256>2561281288161616640.5B2
  • a The first two numbers, separated by a slash, indicate the year and month of isolation, respectively.

  • b Days between admission and the isolation of SIM-1-producing A. baumannii.

  • c Abbreviations: SAM, ampicillin-sulbactam; PIP, piperacillin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; ATM, aztreonam; IPM, imipenem; MEM, meropenem; GEN, gentamicin; TOB, tobramycin; AMK, amikacin; CIP, ciprofloxacin; ROX, roxithromycin; FMX, flomoxef; ISP, isepamycin; CFM, cefixime; AMC, amoxicillin-clavulanate; SXT, trimethoprim-sulfamethoxazole; NA, not applicable; UTI, urinary tract infection.